Recon: AstraZeneca announces $15B China investment; UK says severe pancreatitis and death linked to GLP-1 drugs
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- US vaccine changes lead some parents to question other newborn care (Reuters)
- Lilly, Repertoire enter up to $1.93 billion deal to develop autoimmune therapies (Reuters)
- How Opvee, Indivior’s powerful overdose antidote, went bust (STAT)
- Medicare proposes new transplant system rules that might spur use of less-than-perfect organs (STAT)
- Trump administration signals there’s widespread desire to curb Medicare Advantage (STAT)
- With new vaccine schedule secured, RFK Jr. allies head to statehouses (STAT)
- ARS Pharma TV ad for Neffy needled by FDA in untitled letter (Fierce Pharma)
- Sanofi vaccine sales face headwinds from US policy shifts (Reuters)
- US names HIV, arthritis drugs for next Medicare price talks (Reuters)
- Elon Musk's Neuralink says it has 21 participants enrolled in trials (Reuters)
- AstraZeneca sets out $15 billion China investment during Starmer visit (Reuters)
- Roche earnings edge up 5% as forex effects weigh on drug sales growth (Reuters)
- Pressure grows on ministers to end secrecy over UK medicines deal with Trump (The Guardian)
- Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff (Endpoints)
- Pakistan becomes latest Asian country to introduce checks for deadly Nipah virus (Reuters)
- UK Warns of Severe Pancreatitis, Deaths Tied to Wegovy, Mounjaro (Bloomberg)
- Covid Left Lasting Rise in Deaths in Rich Countries, Study Shows (Bloomberg)
- AI biotech founded by ex-Google CEO Eric Schmidt is raising $150 million (STAT)
- US FDA places clinical hold on Regenxbio's rare disease program (Reuters)
- ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say (STAT)
- Why I decided to share all my health information with ChatGPT Health (STAT)
- Agomab anticipates $182M IPO as it builds fibrosis pipeline (Endpoints)
- Summit says FDA will decide to approve its cancer drug by November (Endpoints)
- Sanofi vows to stay committed to vaccines as portfolio takes a hit (Endpoints)
- The disrupted fate of pharmacy startups (Endpoints)
- CDRH on track for review timelines despite staff cuts (MedTech Dive)
- Thermo Fisher forecasts 2026 profit below estimates on research funding cuts (Reuters)
- Cleveland Diagnostics names Michael Iskra CEO (MedTech Dive)
- Medtech M&A took off in the second half of 2025: report (MedTech Dive)
- Hey Doc, What’s That Sound? FDA Clearance Broadens Scope Of AI Heart Murmur Detection Platform (MedTech Insight)
- Illumina Pins 2026 Growth On Clinical Sequencing As Research Spending Stays Constrained (MedTech Insight)
- When Brain-Computer Interfaces Fail, Human Trial Participants Have Few Options (MedTech Insight)
- It’s Trendy to Mimic Breast Milk, But Formula Makers May Be Adding Risks (Bloomberg)
- Bain, Blackstone Among Suitors for UK Vitamin Maker Vitabiotics (Bloomberg)
- US life expectancy hit an all-time high in 2024, CDC says (STAT)
- HHS appoints 21 new members to federal autism advisory committee (STAT)
- Secretary Kennedy names new chair, 10 members to federal Alzheimer's advisory panel (Reuters)
- Kaiser Permanente, DOJ reach $556 million Medicare Advantage fraud settlement, the largest of its kind (STAT)
- Do pediatricians make large profits from vaccines? (STAT)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
